Trevi Therapeutics Q4 Earnings Call Highlights

Trevi Therapeutics (NASDAQ: TRVI) used its fourth-quarter and year-end 2025 earnings call to outline next steps following what management described as a pivotal year driven by positive clinical data in two chronic cough programs. President and CEO Jennifer Good said 2025 marked a "major inflection point" for the company after favorable readouts from the CORAL trial